Artelo Biosciences, Inc. Transition report pursuant to Rule 13a-10 or 15d-10

Transition report pursuant to Rule 13a-10 or 15d-10

EQUITY (Tables)

EQUITY (Tables)

4 Months Ended

Dec. 31, 2021

Schedule of activity warrants outstanding

		Number of shares				Weighted Average Exercise Price				Weighted Average Life (years)
Outstanding, August 31, 2019			2,334,937			$	8.12				4.14
Granted			-				-				-
Forfeited			-				-				-
Exercised			-				-				-
Outstanding, August 31, 2020			2,334,937			$	8.12				3.30
Granted			10,120,000				0.75				5.00
Forfeited			-				-				-
Exercised			(8,021,525	)			(0.75	)			(4.68	)
Outstanding, August 31, 2021			4,433,412			$	4.63				3.16
Granted			-				-				-
Forfeited			-				-				-
Exercised			-				-				-
Outstanding, December 31, 2021			4,433,412			$	4.63				2.83

Schedule of stock option assumptions

		Four months ended December 31,				Year ended August 31,				Year ended August 31,
		2021				2021				2020
Expected term			6 - 6.25 years				5 years				5 years
Expected average volatility			144 - 158	%			151 - 157	%			155	%
Expected dividend yield			-				-				-
Risk-free interest rate			1.13 - 1.15	%			0.36 - 0.79	%			1.67	%

Schedule of stock option activity

		Options Outstanding								Weighted Average
		Number of Options				Weighted Average Exercise Price				Remaining life (years)

Outstanding, August 31, 2019			234,000			$	3.88				9.78
Granted			74,000				2.48				10.00
Exercised			-				-				-
Forfeited/canceled			(26,166	)			(3.31	)			(9.58	)
Outstanding, August 31, 2020			281,834			$	3.57				8.90
Granted			2,755,100				2.28				10.00
Exercised			-				-				-
Forfeited/canceled			(177,750	)			(2.57	)			(8.33	)
Outstanding, August 31, 2021			2,859,184			$	2.39				9.27
Granted			2,149,800				0.63				10.00
Exercised			-				-				-
Forfeited/canceled			-				-				-
Outstanding, December 31, 2021			5,008,984			$	1.63				9.36

Exercisable options, December 31, 2021			342,350			$	3.29				7.58